Riskpilot← Back to searchSign inGet full accessNEOGAP Therapeutics AB
ABActiveOrg 5590533658Visionsgatan 56 Karolinska (Cck)Research and experimental development on natural sciences and engineering · NACE 7210Est. 201617 employees
Revenue 2024
SEK 30,5M
EBITDA margin
-19.5%
-9% vs 2023
Equity ratio
40.6%
Financial strength
Net profit 2024
SEK -5,7M
+50% vs 2023
| Revenue | SEK 30,5M | — |
| EBITDA | SEK -5,9M | -9% |
| Net profit | SEK -5,7M | +50% |
| Total assets | SEK 105,5M | -14% |
| Equity | SEK 42,8M | -12% |
| Employees | 17 | — |
Legal name
NEOGAP Therapeutics AB
Org number
5590533658
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 mars 2016
Share capital
SEK 133 140
Employees
17 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att direkt eller indirekt bedriva forskning och utveckling av läkemedel och medicintekniska produkter samt idka därmed förenlig verksamhet.
Address
Visionsgatan 56 Karolinska (Cck)
Email
samuel.svensson@neogap.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 30 457 |
| Staff expenses | — | — | — | — | −14 683 |
| EBITDA | −1 238 | −8 970 | −2 576 | −5 455 | −5 936 |
| Depreciation & amort. | −194 | −212 | −56 683 | −424 | −366 |
| EBIT | −1 432 | −9 182 | −59 259 | −5 879 | −6 303 |
| Net financials | −485 | −926 | −2 550 | −5 805 | 580 |
| Profit before tax | −1 818 | −10 108 | −60 534 | −11 444 | −5 722 |
| Tax | −20 | −0 | −0 | −0 | — |
| Net profit | −1 838 | −10 108 | −60 534 | −11 444 | −5 722 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 78 564 | 124 454 | 63 571 | 122 156 | 105 542 |
| Equity | 18 206 | 66 507 | 5 973 | 48 547 | 42 824 |
| Long-term debt | 0 | 53 499 | 53 499 | 53 499 | 53 499 |
| Short-term debt | 60 358 | 4 448 | 4 099 | 20 110 | 9 219 |
| Total debt | 60 358 | 57 947 | 57 598 | 73 609 | 62 718 |
EBITDA margin
-19.5%
This company
15.8%
Market median
-223% vs market
20202024
Equity ratio
40.6%
This company
38.2%
Market median
+6% vs market
20202024
Return on equity
-13.4%
This company
18.4%
Market median
-173% vs market
20202024
Net profit margin
-18.8%
This company
8.1%
Market median
-332% vs market
20202024
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20202024
Debt / equity
1.46×
This company
0.62×
Market median
-135% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MN Chief Auditor | Chief Auditor | 2022 |
SP Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Chairman | 2022 | |
| Board of Directors | 2021 | |
| Board of Directors | 2022 | |
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Former (3) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2025 | |
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NEOGAP Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikael Nilsson | Chief Auditor | 0 companies |
| Samuel Pär Simon Svensson | Chief Executive Officer | 0 companies |
| Hans Anders Conrad Grönlund | Board of Directors | 0 companies |
| Johan Lars Fredrik Lund | Chairman | 0 companies |
| Anna Maria Kälvemark | Board of Directors | 0 companies |
| Sven Thomas Grönlund | Board of Directors | 0 companies |
| Charles Steven Glavas | Board of Directors | 0 companies |
| Björn Nils Tage Bloth | Chairman | 0 companies |
| Guro Annika Gafvelin | Board of Directors | 0 companies |
| Jonas Ingemar Mattsson | Board of Directors | 0 companies |
| Knut Lars-Erik Andersson | Board of Directors | 0 companies |